Quince Therapeutics：eDSP 用于 A-T 的 3 期 NEAT 试验主要数据预计于 2026 年第一季度公布

该公司已完成关键性 3 期 NEAT 试验（共 105 名受试者）的入组，并确认主要数据将于 2026 年第一季度公布。该试验仍处于 FDA 特别方案评估之下，阳性数据将支持计划于 2026 年下半年提交 NDA。

关键事实

申报时间: 2025年11月12日 21:05
事件: 顶线结果
方向: 中性
公司: QNCXQuince Therapeutics, Inc.
资产: eDSP
来源: SEC 8-K
可信度: 有来源
效能: 约90%
参与者: 105
ole参与率: 100%
主要分析人群: 83

来源摘录

EX-99.1 2 qncx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline results expected in first quarter of 2026 SOUTH SAN FRANCISCO, Calif. – November 12, 2025 – Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the third quarter ended September 30, 2025. Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Quince remains on track to report

SEC 8-K